Brought to you by 
Baxter gets rights to Chatham’s hemophilia B gene therapeutic AskBio009
25 Sep 2020
Executive Summary
Chatham Therapeutics LLC (the hemophilia-focused affiliate of large-molecule delivery company Asklepios BioPharmaceutical Inc. (AskBio)) has licensed Baxter BioScience (the recombinant and plasma-based proteins division of Baxter International Inc.’s Baxter Healthcare Corp.) exclusive worldwide rights to its Phase I gene therapeutic AskBio009 for hemophilia B, a single-gene disorder caused by deficient gene coding on the X chromosome of the blood clotting Factor IX.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com